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therapy among those who cannot tolerate statins.
OBJECTIVES This study determined time trends between 2007 and 2011 for statin and nonstatin lipid-lowering
therapy (niacin, ﬁbrates, bile acid sequestrants, and ezetimibe) use among Medicare beneﬁciaries with coronary heart
disease (CHD) in light of emerging clinical trial evidence.
METHODS We conducted a retrospective cohort study using the national 5% random sample of Medicare beneﬁciaries
(n ¼ 310,091). We created 20 cohorts of individuals with CHD, representing calendar quarters from 2007 through 2011,
to assess trends in use of statins and nonstatin lipid-lowering medications.
RESULTS Statin use increased from 53.1% to 58.8% between 2007 and 2011. Ezetimibe use peaked at 12.1% and
declined to 4.6% by the end of 2011, declining among both patients on statins (18.4% to 6.2%) and not on statins
(5.0% to 2.4%). Fibrate use increased from 4.2% to 5.0%, bile acid sequestrants did not change signiﬁcantly, and niacin
use increased from 1.5% to 2.4% and then declined in late 2011. Use of nonstatin lipid-lowering therapy was less
common at older age, among African Americans, patients with heart failure, and patients with a higher Charlson
comorbidity score. Nonstatin lipid-lowering therapy use was more common among men and patients with diabetes,
those who had cardiologist visits, and among those taking statins.
CONCLUSIONS Declining ezetimibe and niacin use but not ﬁbrate therapy among Medicare beneﬁciaries with CHD
coincides with negative clinical trial results for these agents. (J Am Coll Cardiol 2015;66:1864–72)
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AB BR EV I A T I O N S
AND ACRONYM S
CHD = coronary heart disease
CI = conﬁdence interval
ICD-9-CM = International
Classiﬁcation of Diseases-Ninth
Edition-Clinical Modiﬁcation
RR = risk ratio
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1865and poor adherence or inability to tolerate prescribed
therapies for secondary prevention. Among individ-
uals with residual dyslipidemia on a statin, com-
bination lipid-lowering therapy (statin plus niacin,
ﬁbrate, bile acid sequestrant, or ezetimibe) further
lowers low-density lipoprotein cholesterol and
nonhigh-density lipoprotein cholesterol and may
decrease triglycerides and increase high-density lipo-
protein cholesterol (3). The evidence for additional
reduction in cardiovascular risk with combination
therapy is limited (4), although recent results from
the IMPROVE-IT (IMProved Reduction of Outcomes:
Vytorin Efﬁcacy International Trial) showed a modest
reduction in cardiovascular events from additional
low-density lipoprotein cholesterollowering with
ezetimibe added to simvastatin compared to simva-
statin monotherapy in patients with acute coronary
syndrome (5). Nonstatin lipid-lowering therapy is
also used among individuals unable to take statins
given favorable outcomes with bile acid sequestrants,
ﬁbrates, and niacin in older randomized controlled
outcomes trials and angiographic regression trials (3).SEE PAGE 1873Using pharmaceutical sales and prescription data
from the United States and Canada, several reports
have emphasized changes over time in the use of
ezetimibe, niacin, and ﬁbrates (6–11). However, these
studies did not report trends of therapy among pa-
tients with CHD and did not assess clinical correlates
of nonstatin lipid-lowering therapy. In this study, we
report trends between 2007 and 2011 in the use of
niacin, ﬁbrates, bile acid sequestrants, and ezetimibe
alone and in combination with statin therapy among
Medicare beneﬁciaries with CHD.
METHODS
We conducted a retrospective cohort study of Medi-
care beneﬁciaries using the 20062011 national 5%
random sample from the Centers for Medicare and
Medicaid Services. Medicare is a U.S. federal beneﬁt
program that provides health insurance to individuals
who are $65 years of age, on disability, or who have
end-stage renal disease, through either fee-for-service
reimbursement or through contracts with health care
organizations (Medicare Advantage). For the current
analysis, we used claims data from Medicare fee-for-
service Parts A (inpatient), B (outpatient), and D (pre-
scription drug). Medicare claims and assessment data
are linked by beneﬁciary across the continuum of care.
We excluded beneﬁciaries enrolled in Medicare
Advantage plans (Medicare Part C) as claims for these
individuals are not complete. Centers for Medicareand Medicaid Services and the Institutional
Review Board at the University of Alabama at
Birmingham approved the study.
The calendar years of 2007 through 2011
were divided into 20 quarters deﬁned as
January 1 to March 31 (ﬁrst quarter), April 1 to
June 30 (second quarter), July 1 to September
30 (third quarter), and October 1 to December
31 (fourth quarter). For each calendar quarter,
we deﬁned an eligibility period as the 1 year before the
start of the quarter (Online Figure 1). To be eligible for a
calendar quarter, beneﬁciaries were required to meet
the following criteria: 1) be$65 years of age at the start
of the eligibility period; 2) have a history of CHD
documented during the look-back period; and 3) have
continuous “full coverage” for Medicare, be in the 5%
Medicare sample, and live in the United States for the
entire eligibility period and calendar quarter under
study. We deﬁned the look-back period as the time
between the start of the eligibility period through the
date of the ﬁrst nonstatin lipid-lowering medication
ﬁll in the calendar quarter under study or as the
midpoint of the calendar quarter for beneﬁciaries who
did not ﬁll a nonstatin lipid-lowering medication.
Additionally, we excluded beneﬁciaries who died
before the end of the calendar quarter under study.We
used an algorithm based on International Classiﬁca-
tion of Diseases-Ninth Edition-Clinical Modiﬁcation
(ICD-9-CM) and current procedure terminology codes
to deﬁne a history of CHD (Online Table 1). Full
Medicare coverage was deﬁned as enrollment in
Medicare fee-for-service (Parts A and B) and Part D and
not being enrolled in a Medicare Advantage plan.
LIPID-LOWERING MEDICATION USE. We investi-
gated the use of statins, overall and by intensity
(high or low/moderate), and nonstatin lipid-lowering
medications. Seven statins were studied (atorvasta-
tin, ﬂuvastatin, lovastatin, pitavastatin, pravastatin,
rosuvastatin, and simvastatin). High-intensity statins
included a ﬁll for atorvastatin 40 or 80 mg, rosuva-
statin 20 or 40 mg, and simvastatin 80 mg. Nonstatin
lipid-lowering medications included ezetimibe, ﬁb-
rates, niacin, and bile acid sequestrants. Participants
were considered to be taking amedication if they had a
prescription ﬁll during the calendar quarter under
study. Medication use was identiﬁed using National
Drug Codes and Medicare Part D pharmacy claims.
COVARIATES. We obtained age, sex, race/ethnicity,
and receipt of a low-income subsidy under Medicare
Part D or Medicare/Medicaid dual eligibility from the
Medicare beneﬁciary enrollment ﬁle. Each beneﬁ-
ciary’s age was based on the date of their ﬁrst ﬁll of a
nonstatin lipid-lowering medication or the midpoint
FIGURE 1 Use of Statins Among Medicare Beneﬁciaries With CHD in 2007 to 2011 by
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1866of the calendar quarter for beneﬁciaries who did not ﬁll
a nonstatin lipid-lowering medication. Comorbid
conditions, Charlson comorbidity score, residence in a
skilled nursing facility, having received cardiologist
care, and the number of different medications ﬁlledonstatin Lipid-Lowering Medications Among Medicare Beneﬁciaries
gh Potency Statins, Low/Moderate Potency Statins and Not
07 to 2011 by Calendar Quarter
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s deﬁned as 40 to 80 mg atorvastatin, 20 to 40 mg rosuvastatin,were deﬁned using previously published algorithms
and ICD-9-CM codes (12–17). Hospitalizations in
the look-back period were categorized as being
CHD-related (myocardial infarction, coronary artery
bypass grafting, percutaneous coronary intervention)
or not.
STATISTICAL ANALYSES. We ﬁrst calculated the
proportion of Medicare beneﬁciaries with CHD who
ﬁlled a statin, overall and by intensity, and nonstatin
lipid-lowering medication during each calendar
quarter from JanuaryMarch (quarter 1) 2007 through
OctoberDecember (quarter 4) 2011. Taking nonstatin
lipid-lowering medications was calculated overall
and for beneﬁciaries taking and not taking statins,
separately. Additionally, the proportion of Medicare
beneﬁciaries with CHD taking ezetimibe, ﬁbrates,
niacin, and bile acid sequestrants, separately, was
calculated for each calendar quarter.
For the remainder of analyses, we pooled data for
the 20 calendar quarters. Characteristics of Medicare
beneﬁciaries with CHD taking and not taking non-
statin lipid-lowering medication were calculated. As
beneﬁciaries could contribute to each of the 20 cal-
endar quarters under study, generalizable estimating
equations were used to determine the statistical sig-
niﬁcance of differences across these 2 groups. Using
Poisson regression with sandwich estimators ac-
counting for repeated measures, we calculated risk
ratios (RRs) and 95% conﬁdence intervals (CIs) for
ﬁlling a nonstatin lipid-lowering medication associ-
ated with calendar year, age, sex, race/ethnicity, low
socio-economic status, diabetes, CHD and non-CHD
related hospitalization in the past year, history of
stroke, history of heart failure, Charlson index,
skilled nursing facility stay, cardiologist care, use
of statins, and total number of medications being
administered. RRs were calculated in unadjusted
models, after age, sex, race/ethnicity adjustment,
and in a model that included all covariates simulta-
neously. Poisson regression is a log-linear model that
can be used with binary outcomes. When outcomes
are common, it has the advantage of providing a more
accurate estimate of an exposure-outcome associa-
tion compared with odds ratios produced by logistic
regression. In a ﬁnal analysis, the fully adjusted
model was also calculated for beneﬁciaries taking and
not taking statins, separately. All data management
and statistical analyses were conducted using SAS
version 9.3 (SAS Institute, Cary, North Carolina).
RESULTS
The current analysis included 310,091 Medicare
beneﬁciaries. In the ﬁrst quarter of 2007, 53.1% of
CENTRAL ILLUSTRATION Nonstatin Lipid-Lowering Therapy in Medicare: Use of Ezetimibe, Fibrates, Niacin, and
Bile Acid Sequestrants Among Medicare Beneﬁciaries With CHD in 2007 Through 2011 by Calendar Quarter
Press Release 
   AIM HIGH
Press Release AIM HIGH
Publication
  ACCORD
Publication
  ACCORD
Press Release
   ENHANCE
Press Release
   ENHANCE
Bittner, V. et al. J Am Coll Cardiol. 2015; 66(17):1864–72.
A
B
(A) Shows data for Medicare beneﬁciaries on statins. (B) Shows data for Medicare beneﬁciaries not on statins. Arrows indicate time points
when key study results were released. ENHANCE ¼ Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression;
ACCORD ¼ Action to Control Cardiovascular Risk in Diabetes; AIM HIGH ¼ Atherothrombosis Intervention in Metabolic Syndrome with Low
HDL/High Triglycerides: Impact on Global Health Outcomes.
J A C C V O L . 6 6 , N O . 1 7 , 2 0 1 5 Bittner et al.
O C T O B E R 2 7 , 2 0 1 5 : 1 8 6 4 – 7 2 Nonstatin Lipid-Lowering Therapy in Medicare
1867
TABLE 1 Characteristics of Medicare Beneﬁciaries With CHD Taking and
Not Taking Nonstatin Lipid-Lowering Medication in 2007 to 2011
Use of Nonstatin Lipid-Lowering
Medication
No
(n ¼ 2,267,380)
Yes
(n ¼ 367,151)
Calendar year
2007 367,698 (16.2) 75,247 (20.5)
2008 453,174 (20.0) 80,376 (21.9)
2009 471,383 (20.8) 71,582 (19.5)
2010 479,010 (21.1) 70,477 (19.2)
2011 496,115 (21.9) 69,469 (18.9)
Age, yrs
<70 333,182 (14.7) 79,049 (21.5)
70–74 481,974 (21.3) 100,548 (27.4)
75–79 477,695 (21.1) 84,336 (23.0)
80–84 455,817 (20.1) 62,711 (17.1)
$85 518,712 (22.9) 40,507 (11.0)
Male 1,011,652 (44.6) 188,939 (51.5)
Race/ethnicity
White 1,924,531 (84.9) 327,484 (89.2)
African American 177,825 (7.8) 16,158 (4.4)
Other 41,052 (1.8) 6,311 (1.7)
Asian American 55,140 (2.4) 8,124 (2.2)
Hispanic American 68,832 (3.0) 9,074 (2.5)
Low income subsidy/dual eligible 908,203 (40.1) 132,297 (36.0)
History of diabetes 793,141 (35.0) 155,758 (42.4)
CHD hospitalization 166,020 (7.3) 25,975 (7.1)
Non-CHD hospitalization 792,471 (35.0) 101,214 (27.6)
History of stroke 185,798 (8.2) 22,709 (6.2)
History of heart failure 689,213 (30.4) 90,661 (24.7)
Charlson index
0 386,173 (17.0) 67,512 (18.4)
1–3 909,130 (40.1) 155,469 (42.3)
$4 972,077 (42.9) 144,170 (39.3)
Skilled nursing facility stay 291,266 (12.8) 25,174 (6.9)
Cardiologist care 1,433,906 (63.2) 273,661 (74.5)
Use of statins 1,218,466 (53.7) 264,960 (72.2)
Number of medications taken*
<5 253,045 (11.2) 37,236 (10.1)
5–9 697,965 (30.8) 115,166 (31.4)
$10 1,316,370 (58.1) 214,749 (58.5)
Values are n (%). *Not including statins or other lipid-lowering medications. As described in
the Methods, beneﬁciaries could contribute multiple records between 2007 and 2011. Overall,
there were 310,091 unique beneﬁciaries included in this analysis (n ¼ 62,638 using nonstatin
lipid-lowering medication). All p values for comparisons are <0.001. Though statistically sig-
niﬁcant, some differences are likely unimportant.
CHD ¼ coronary heart disease.
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1868Medicare beneﬁciaries with CHD ﬁlled a statin pre-
scription with 11.1% having received a high-intensity
statin (Figure 1). The use of statins increased over
time and 58.8% and 14.2% of Medicare beneﬁciaries
with a history of CHD ﬁlled any statin and a high-
intensity statin, respectively, in the fourth quarter
of 2011. The use of nonstatin lipid-lowering medica-
tion did not change substantially between the ﬁrstquarter of 2007 and 2008, but declined thereafter
from 16.8% in the ﬁrst quarter of 2008 to 11.7% in the
fourth quarter of 2011. Use of nonstatin lipid-lowering
therapy decreased substantially more among statin
users than non-users (Figure 2).
In the overall population with CHD, ezetimibe use
peaked at 12.1% in 2007 and declined to 4.6% by the
end of 2011. Fibrate use increased from 4.2% to 5.0%,
bile acid sequestrants did not change signiﬁcantly,
and niacin use increased from 1.5% to 2.4% and then
modestly declined in late 2011. Among those on sta-
tins, ezetimibe use declined from a peak of 18.4% in
2007 to 6.2% by the fourth quarter of 2011 (Central
Illustration). Niacin use increased from 2.2% in the
ﬁrst quarter of 2007 to a peak of 3.1% in the ﬁrst
quarter of 2011 and declined to 2.7% by the fourth
quarter of 2011. Fibrate use gradually increased from
4.7% to 5.5% over this period. Bile acid sequestrant
use was low (0.5% to 0.8%) throughout the study
period. Patterns of use of nonstatin lipid-lowering
medications were similar for high-intensity statin
and low-/moderate- intensity statin users (Online
Figure 2).
Among those not on statins (Central Illustration),
ezetimibe use was less common throughout the study
period than among statin users. Temporal trends,
however, were similar with ezetimibe use declining
from 5.0% in the fourth quarter of 2007 to 2.4% in the
fourth quarter of 2011. In contrast, ﬁbrate use was
more common among those not on statins than those
on statins and increased over time among those not
on statins, surpassing ezetimibe use by the third
quarter of 2008. Only a small percentage of nonstatin
users were on bile acid sequestrants or niacin.
Publication dates of key clinical trials concerning
nonstatin lipid-lowering medications are shown in
the Central Illustration and Online Figure 2 and
suggest a temporal relationship between negative
trial announcement or publication for ezetimibe and
niacin, but not for ﬁbrates.
Differences in demographics, comorbidities, and
health care use between Medicare beneﬁciaries
with CHD taking and not taking nonstatin lipid-
lowering medications are detailed in Table 1. These
differences were similar across the study period
(Online Table 2). In both crude and age-, sex-, and
race/ethnicity-adjusted models, the use of nonstatin
lipid-lowering medication decreased over successive
calendar years and was lower at older age and among
African Americans, Asian Americans, and Hispanics,
compared to whites (Table 2). Being male, having
diabetes, receiving care from a cardiologist, taking
statins, and taking more medications overall
were associated with a higher RR of nonstatin
TABLE 2 Risk Ratios for Taking Nonstatin Lipid-Lowering Medications Among
Medicare Beneﬁciaries With CHD
Risk Ratio (95% CI)
Crude
Age, Sex,
Race/Ethnicity
Adjusted
Multivariable
Adjusted
Calendar year
2007 1.00 (ref) 1.00 (ref) 1.00 (ref)
2008 0.89 (0.88–0.89) 0.88 (0.88–0.89) 0.87 (0.86–0.88)
2009 0.78 (0.77–0.79) 0.77 (0.76–0.78) 0.75 (0.74–0.75)
2010 0.76 (0.74–0.77) 0.75 (0.74–0.76) 0.71 (0.70–0.72)
2011 0.72 (0.71–0.73) 0.72 (0.71–0.73) 0.67 (0.66–0.68)
Age, yrs
<70 1.00 (ref) 1.00 (ref) 1.00 (ref)
70–74 0.90 (0.88–0.92) 0.90 (0.88–0.92) 0.91 (0.89–0.93)
75–79 0.78 (0.76–0.80) 0.79 (0.77–0.80) 0.81 (0.79–0.83)
80–84 0.63 (0.61–0.65) 0.64 (0.62–0.65) 0.69 (0.68–0.71)
$85 0.38 (0.37–0.39) 0.38 (0.37–0.40) 0.48 (0.47–0.50)
Male 1.27 (1.24–1.29) 1.11 (1.09–1.13) 1.09 (1.07–1.11)
Race/ethnicity
White 1.00 (ref) 1.00 (ref) 1.00 (ref)
African American 0.57 (0.55–0.60) 0.56 (0.54–0.59) 0.59 (0.57–0.62)
Other 0.92 (0.85–0.98) 0.85 (0.80–0.92) 0.86 (0.80–0.92)
Asian American 0.88 (0.83–0.94) 0.88 (0.83–0.93) 0.82 (0.77–0.88)
Hispanic American 0.80 (0.76–0.85) 0.84 (0.79–0.89) 0.82 (0.77–0.86)
Low income subsidy/dual eligible 0.86 (0.85–0.88) 0.97 (0.95–0.99) 1.00 (0.98–1.02)
History of diabetes 1.31 (1.29–1.33) 1.28 (1.26–1.30) 1.30 (1.28–1.32)
CHD hospitalization 0.97 (0.95–0.99) 0.94 (0.92–0.96) 0.81 (0.80–0.83)
Non-CHD hospitalization 0.74 (0.73–0.75) 0.81 (0.80–0.82) 0.85 (0.84–0.87)
History of stroke 0.77 (0.75–0.79) 0.85 (0.82–0.87) 0.93 (0.90–0.96)
History of heart failure 0.78 (0.77–0.79) 0.88 (0.87–0.90) 0.89 (0.88–0.91)
Charlson index
0 1.00 (ref) 1.00 (ref) 1.00 (ref)
13 0.98 (0.96–1.00) 1.02 (1.00–1.04) 0.93 (0.92–0.95)
$4 0.87 (0.85–0.89) 0.97 (0.95–1.00) 0.95 (0.92–0.97)
Skilled nursing facility stay 0.54 (0.53–0.55) 0.65 (0.64–0.67) 0.80 (0.78–0.82)
Cardiologist care 1.59 (1.56–1.62) 1.45 (1.42–1.47) 1.38 (1.35–1.40)
Use of statins 2.01 (1.98–2.05) 1.86 (1.83–1.90) 1.77 (1.74–1.81)
Total number of medications taken*
<5 1.00 (ref) 1.00 (ref) 1.00 (ref)
5–9 1.10 (1.08–1.13) 1.18 (1.15–1.20) 1.10 (1.08–1.13)
$10 1.09 (1.07–1.12) 1.21 (1.18–1.25) 1.19 (1.16–1.22)
*Not including statins or nonstatin lipid-lowering therapy. Multivariable adjusted model includes all variables
listed in a single model.
CHD ¼ coronary heart disease; CI ¼ conﬁdence interval.
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lipid-lowering medication use was less common
among beneﬁciaries with CHD- or nonCHD-related
hospitalizations in the prior year, with a history of
heart failure or stroke, or with a stay in a skilled
nursing facility.
After multivariable adjustment, declining use of
nonstatin lipid-lowering medication by calendar year
was more evident among statin users than nonusers
(Table 3). History of diabetes, cardiologist care, and
number of medications administered were associated
with an increased risk of nonstatin lipid-lowering
medication use in both groups, but the association
was more pronounced among those not taking sta-
tins. History of skilled nursing facility stay was
associated with a lower risk for nonstatin lipid-
lowering medication use in both groups. Having
CHD hospitalizations were more strongly associated
with not using nonstatin lipid-lowering therapy
among statin users. The Charlson index was more
strongly associated with lower use of nonstatin
lipid-lowering medications among those not taking
statins.
DISCUSSION
Among Medicare beneﬁciaries with CHD, use of
nonstatin lipid-lowering therapy has declined be-
tween 2008 and 2011 primarily due to a marked
reduction in the use of ezetimibe, even though
national cholesterol guidelines and treatment targets
remained unchanged during the study period. This
decrease in nonstatin lipid-lowering therapy occurred
both among patients taking statins and not taking
statins, but was more pronounced among statin
users. Time trends in use of nonstatin lipid-lowering
medications other than ezetimibe were less pro-
nounced and heterogeneous. In any given calendar
quarter, <60% of Medicare beneﬁciaries with CHD
ﬁlled a statin. Statin use was low at the beginning of
the observation period and increased only modestly
over time despite good evidence for efﬁcacy to at
least age 75 years and likely beyond and guideline
recommendations in favor of statin use in these
high-risk individuals.
As others have reported based on data from IMS
Health (Danbury, Connecticut) and pharmacy beneﬁt
managers (10,11,18), the decline in ezetimibe therapy
in this Medicare cohort with CHD temporally co-
incides with the announcement and publication of
the ENHANCE (Ezetimibe and Simvastatin in Hyper-
cholesterolemia Enhances Atherosclerosis Regres-
sion) trial (a small trial that assessed changes in
carotid intimal medial thickness among patients withfamilial hypercholesterolemia), related media cover-
age, and an announcement by the U.S. Food and Drug
Administration of an ongoing review of the drug
after the SEAS (Simvastatin and Ezetimibe in Aortic
Stenosis) trial raised the possibility of an increased
risk of malignancy (19,20). This malignancy risk
was not conﬁrmed in subsequent pooled analyses of
ezetimibe data (21). While much of the decline in
ezetimibe use is likely related to fewer prescriptions
written by physicians, increased nonpersistence with
TABLE 3 Risk Ratios for Taking Nonstatin Lipid-Lowering Medications
Among Medicare Beneﬁciaries With CHD
Multivariable Adjusted
Risk Ratios (95% CI)
Not Taking Statins Taking Statins
Calendar year
2007 1.00 (ref) 1.00 (ref)
2008 0.91 (0.89–0.93) 0.86 (0.85–0.86)
2009 0.87 (0.85–0.89) 0.70 (0.69–0.71)
2010 0.89 (0.87–0.91) 0.65 (0.64–0.66)
2011 0.86 (0.83–0.88) 0.61 (0.60–0.62)
Age, yrs
<70 1.00 (ref) 1.00 (ref)
70–74 0.96 (0.93–0.99) 0.89 (0.87–0.91)
75–79 0.88 (0.85–0.92) 0.79 (0.77–0.81)
80–84 0.78 (0.75–0.82) 0.67 (0.65–0.69)
$85 0.51 (0.48–0.54) 0.48 (0.47–0.50)
Male 1.07 (1.04–1.11) 1.10 (1.08–1.12)
Race/ethnicity
White 1.00 (ref) 1.00 (ref)
African American 0.50 (0.47–0.54) 0.63 (0.60–0.67)
Other 0.83 (0.74–0.93) 0.87 (0.81–0.95)
Asian American 0.97 (0.87–1.07) 0.78 (0.72–0.83)
Hispanic American 0.78 (0.71–0.86) 0.83 (0.78–0.89)
Low income subsidy/dual eligible 0.96 (0.93–1.00) 1.03 (1.01–1.05)
History of diabetes 1.53 (1.48–1.58) 1.22 (1.19–1.24)
CHD hospitalization 0.95 (0.91–0.99) 0.78 (0.76–0.80)
Non-CHD hospitalization 0.82 (0.80–0.84) 0.87 (0.86–0.89)
History of stroke 0.96 (0.92–1.01) 0.91 (0.88–0.94)
History of heart failure 0.83 (0.80–0.86) 0.92 (0.90–0.94)
Charlson index
0 1.00 (ref) 1.00 (ref)
1–3 0.91 (0.88–0.95) 0.95 (0.93–0.97)
$4 0.89 (0.85–0.93) 0.98 (0.96–1.01)
Skilled nursing facility stay 0.76 (0.73–0.79) 0.82 (0.80–0.85)
Cardiologist care 1.57 (1.52–1.62) 1.29 (1.27–1.32)
Total number of medications taken*
<5 1.00 (ref) 1.00 (ref)
5–9 1.49 (1.42–1.55) 0.98 (0.95–1.00)
$10 1.73 (1.65–1.81) 1.02 (0.99–1.05)
*Not including statins or nonstatin lipid-lowering therapy. Multivariable adjusted model includes
all variables listed in a single model.
Abbreviations as in Table 2.
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1870therapy by patients after the Food and Drug Admin-
istration communication has been reported (22).
Interestingly, a similar decline in ezetimibe use was
not seen in Canada during this same period (10). It is
unknown why these changes in practice by physicians
differ in the United States and Canada.
Rates of ezetimibe use in our Medicare popula-
tion are substantially higher than those described
by others. Rates of ezetimibe use in Express Script
(St. Louis, Missouri) data were approximately one-
ﬁfth of the rates in this study (2.5% compared to
11.4%, respectively) (11). Data from IMS Health alsoshowed substantially lower rates of ezetimibe use
(<1.2%) (10). Characteristics of patients included in
Express Script and IMS Health were not reported.
Although absolute rates of ezetimibe use differed
in these 3 studies, declines in ezetimibe use over
time were very similar suggesting that decision
making by clinicians may have been driven more by
perceptions about ezetimibe than individualized
risk/beneﬁt estimation based on speciﬁc patient
characteristics.
Fibrate use in this Medicare cohort was substan-
tially lower than in IMS Health, but we also saw no
appreciable impact in the use of ﬁbrates after publi-
cation of the ACCORD (Action to Control Cardiovas-
cular Risk in Diabetes) trial in 2010 (7). This large
outcomes trial failed to show a beneﬁt of combina-
tion therapy with a statin and ﬁbrate compared to
statin alone in 5,518 patients with type 2 diabetes
mellitus, one-third of whom had a prior cardiovas-
cular event (23).
Niacin use increased from 1.5% to 2.4% between
the ﬁrst quarter of 2007 and the ﬁrst quarter of 2011
and declined to 2.0% by the fourth quarter of 2011.
This modest decline temporally coincides with a May
26, 2011, National Heart, Lung, and Blood Institute
press brieﬁng about the premature termination of the
AIM HIGH (Atherothrombosis Intervention in Meta-
bolic Syndrome with Low HDL/High Triglycerides)
trial for reasons of futility and concern about
increased rates of stroke with niacin/statin com-
bination therapy. It is not known whether publica-
tion of the ﬁnal AIM HIGH results in November of
2011 led to further declines in Niacin use in subse-
quent years (24).
Bile acid sequestrant use was uncommon
throughout the study period and use did not increase
concomitant with the ezetimibe decline. Such a
substitution would have been rational given cardio-
vascular beneﬁts in clinical trials of bile acid seques-
trants and if additional lipid lowering through
interference with cholesterol handling in the gastro-
intestinal tract was desired (25).
Patient characteristics independently associated
with a higher prevalence of nonstatin lipid lowering
use included younger age, male sex, white race,
history of diabetes, cardiology care, and concomitant
statin therapy. The lower use of nonstatin lipid-
lowering agents among African Americans may be
related to lower prevalence of low high-density lipo-
protein cholesterol and high triglycerides in the
African American population, but deserves further
study. Use of nonstatin lipid-lowering therapy was
more common among beneﬁciaries on more intense
statin regimens. These data suggest that nonstatin
PERSPECTIVES
COMPETENCY IN PATIENT CARE AND PROCEDURAL
SKILLS: Nonstatin lipid-lowering therapy with ezetimibe, niacin,
and/or ﬁbrates, either alone or in combination with statins, is
uncommon in the Medicare population with CHD and has
decreased over time. Many patients with CHD are not taking
statins.
TRANSLATIONAL OUTLOOK: Studies are needed to better
understand the response to evolving clinical evidence by
prescribing clinicians, their patients, regulatory agencies, and
guideline panels.
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1871lipid-lowering therapy was not used as a substitute
for statin therapy or in an attempt to minimize statin
doses, but was instead targeted to individuals based
on perceived higher risk of cardiovascular events and
in need of further intensiﬁcation of lipid-lowering
therapy. In contrast, characteristics of patients on
and off nonstatin lipid-lowering therapy did not
change over time, suggesting that discontinuation of
ezetimibe therapy was not guided by consideration of
speciﬁc patient characteristics but instead by con-
cerns speciﬁc to this medication.
STUDY STRENGTHS AND LIMITATIONS. Our study
has a number of strengths. We analyzed data from a
national cohort of older U.S. adults with CHD, a high-
risk group most likely to beneﬁt from intensive lipid-
lowering therapy. We had data on demographics,
comorbid conditions, and prescription data that
allowed us to identify factors associated with non-
statin lipid-lowering medication use. However, our
study also has limitations. Lipid values are not
available in Medicare claims limiting our ability to
address appropriateness of therapy with speciﬁc
lipid-lowering agents. We were unable to distinguish
whether the decline in ezetimibe and niacin use was a
consequence of fewer prescriptions being written by
physicians or patient decisions to no longer ﬁll their
prescriptions. Many formularies may have excluded
ezetimibe after publication of ENHANCE. As there are
more than 100 drug plans available in Medicare
Part D, examining the association of formularies
and use of ezetimibe was not feasible. Niacin use
in our analysis may be underestimated because
many formulations of niacin are available without
prescription.CONCLUSIONS
Nonstatin lipid-lowering therapy is not commonly
used in the Medicare population with CHD. Temporal
trends in ezetimibe and niacin therapy appeared to
coincide with the announcement and publication of
negative clinical trials evaluating these agents while
an impact of negative trial evidence was not evident
for ﬁbrate use. Studies are needed to better under-
stand the response to clinical evidence by prescribing
clinicians, their patients, regulatory agencies and
guideline panels. Such data will be essential for
the development of better knowledge translation
strategies.
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